Human ADME Studies

How can I simplify the delivery of my Human ADME Study?

Simplifying study delivery while maximizing data output.

Human ADME, Regulatory

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

By: Dr. Adam Robinson-Miller Read Now

Our experts

Iain Shaw is Senior Director of 14C Enabled Drug Development at Quotient Sciences. Iain has over 30 years of experience in the pharmaceutical industry, including more than 20 years of drug development experience and extensive experience with 14C human ADME studies.

Meet Iain

Our capabilities

Our team of experts have extensive chemical and radiochemical knowledge and experience of isotopically labeling hundreds of molecular entities.

Isotopic Labeling

Human ADME Studies: What our customers say

We conducted a 14C human ADME study with Quotient Sciences… We were extremely satisfied with all aspects of the study, including project management, formulation development, manufacture, clinical conduct, and reporting. We would use Quotient Sciences again for this type of study.

Oliver Schueller

SVP, CMC & Clinical Pharmacology , Kadmon, a Sanofi Company

What's new in Human ADME?

Human ADME, First-in-Human Delivering Human ADME Studies By: Iain Shaw

Learn More

Human ADME, Clinical Pharmacology Scientific Poster Spotlight: A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes

Learn More

Candidate Development, First-in-Human How to streamline the development of your molecule from candidate selection to first-in-human clinical testing By: Stephen Byard

Learn More

Humanity can't afford to wait, so neither can we.

Let's talk